Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun 17. doi: 10.1038/s41591-019-0520-5. [Epub ahead of print]

PMID:
31209337
2.

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.

Lancet Oncol. 2019 May 31. pii: S1470-2045(19)30151-2. doi: 10.1016/S1470-2045(19)30151-2. [Epub ahead of print]

PMID:
31160251
3.

Tissue patrol by resident memory CD8+ T cells in human skin.

Dijkgraaf FE, Matos TR, Hoogenboezem M, Toebes M, Vredevoogd DW, Mertz M, van den Broek B, Song JY, Teunissen MBM, Luiten RM, Beltman JB, Schumacher TN.

Nat Immunol. 2019 Jun;20(6):756-764. doi: 10.1038/s41590-019-0404-3. Epub 2019 May 20.

PMID:
31110315
4.

Induction of neoantigen-reactive T cells from healthy donors.

Ali M, Foldvari Z, Giannakopoulou E, Böschen ML, Strønen E, Yang W, Toebes M, Schubert B, Kohlbacher O, Schumacher TN, Olweus J.

Nat Protoc. 2019 Jun;14(6):1926-1943. doi: 10.1038/s41596-019-0170-6. Epub 2019 May 17.

PMID:
31101906
5.

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M.

Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Erratum in: Nat Med. 2019 Jun 17;:.

PMID:
31086347
6.

Breadth and Dynamics of HLA-A2- and HLA-B7-Restricted CD8+ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection.

Lampen MH, Uchtenhagen H, Blom K, Varnaitė R, Pakalniene J, Dailidyte L, Wälchli S, Lindquist L, Mickiene A, Michaëlsson J, Schumacher TN, Ljunggren HG, Sandberg JK, Achour A, Gredmark-Russ S.

Immunohorizons. 2018 Jul 2;2(6):172-184. doi: 10.4049/immunohorizons.1800029.

PMID:
31022685
7.

Publisher Correction: Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer.

Merino D, Weber TS, Serrano A, Vaillant F, Liu K, Pal B, Di Stefano L, Schreuder J, Lin D, Chen Y, Asselin-Labat ML, Schumacher TN, Cameron D, Smyth GK, Papenfuss AT, Lindeman GJ, Visvader JE, Naik SH.

Nat Commun. 2019 Apr 24;10(1):1945. doi: 10.1038/s41467-019-09916-1.

8.

Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells.

Di Lorenzo B, Simões AE, Caiado F, Tieppo P, Correia DV, Carvalho T, da Silva MG, Déchanet-Merville J, Schumacher TN, Prinz I, Norell H, Ravens S, Vermijlen D, Silva-Santos B.

Cancer Immunol Res. 2019 Apr;7(4):552-558. doi: 10.1158/2326-6066.CIR-18-0647. Epub 2019 Mar 20.

PMID:
30894378
9.

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy.

Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NAM, van der Schot S, Marijt KA, Verdoes M, Haanen JBAG, van den Berg JH, Neefjes J, van den Berg TK, Brummelkamp TR, Leusen JHW, Scheeren FA, Schumacher TN.

Nat Med. 2019 Apr;25(4):612-619. doi: 10.1038/s41591-019-0356-z. Epub 2019 Mar 4.

PMID:
30833751
10.

Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity.

Kroon P, Frijlink E, Iglesias-Guimarais V, Volkov A, van Buuren MM, Schumacher TN, Verheij M, Borst J, Verbrugge I.

Cancer Immunol Res. 2019 Apr;7(4):670-682. doi: 10.1158/2326-6066.CIR-18-0654. Epub 2019 Feb 19.

PMID:
30782666
11.

Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer.

Merino D, Weber TS, Serrano A, Vaillant F, Liu K, Pal B, Di Stefano L, Schreuder J, Lin D, Chen Y, Asselin-Labat ML, Schumacher TN, Cameron D, Smyth GK, Papenfuss AT, Lindeman GJ, Visvader JE, Naik SH.

Nat Commun. 2019 Feb 15;10(1):766. doi: 10.1038/s41467-019-08595-2. Erratum in: Nat Commun. 2019 Apr 24;10(1):1945.

12.

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing.

Mezzadra R, de Bruijn M, Jae LT, Gomez-Eerland R, Duursma A, Scheeren FA, Brummelkamp TR, Schumacher TN.

PLoS One. 2019 Feb 12;14(2):e0212053. doi: 10.1371/journal.pone.0212053. eCollection 2019.

13.

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma.

Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi ACJ, van den Braber M, Rozeman EA, Haanen JBAG, Blank CU, Horlings HM, David E, Baran Y, Bercovich A, Lifshitz A, Schumacher TN, Tanay A, Amit I.

Cell. 2019 Feb 7;176(4):775-789.e18. doi: 10.1016/j.cell.2018.11.043. Epub 2018 Dec 27.

PMID:
30595452
14.

Cancer Neoantigens.

Schumacher TN, Scheper W, Kvistborg P.

Annu Rev Immunol. 2019 Apr 26;37:173-200. doi: 10.1146/annurev-immunol-042617-053402. Epub 2018 Dec 14.

PMID:
30550719
15.

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.

Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, Kluin RJC, Snaebjornsson P, Milne K, Nelson BH, Zijlmans H, Kenter G, Voest EE, Haanen JBAG, Schumacher TN.

Nat Med. 2019 Jan;25(1):89-94. doi: 10.1038/s41591-018-0266-5. Epub 2018 Dec 3.

PMID:
30510250
16.

T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide-MHC complexes.

Bentzen AK, Such L, Jensen KK, Marquard AM, Jessen LE, Miller NJ, Church CD, Lyngaa R, Koelle DM, Becker JC, Linnemann C, Schumacher TNM, Marcatili P, Nghiem P, Nielsen M, Hadrup SR.

Nat Biotechnol. 2018 Nov 19. doi: 10.1038/nbt.4303. [Epub ahead of print]

PMID:
30451992
17.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN.

Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.

PMID:
30297911
18.

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, van Rooij N, van Leerdam ME, Depla A, Smit EF, Hartemink KJ, de Groot R, Wolkers MC, Sachs N, Snaebjornsson P, Monkhorst K, Haanen J, Clevers H, Schumacher TN, Voest EE.

Cell. 2018 Sep 6;174(6):1586-1598.e12. doi: 10.1016/j.cell.2018.07.009. Epub 2018 Aug 9.

PMID:
30100188
19.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade.

Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, Savic Prince S, Wiese M, Lardinois D, Ho PC, Klein C, Karanikas V, Mertz KD, Schumacher TN, Zippelius A.

Nat Med. 2018 Jul;24(7):994-1004. doi: 10.1038/s41591-018-0057-z. Epub 2018 Jun 11.

20.

T Cell Dysfunction in Cancer.

Thommen DS, Schumacher TN.

Cancer Cell. 2018 Apr 9;33(4):547-562. doi: 10.1016/j.ccell.2018.03.012. Review.

21.

Regulation and Function of the PD-L1 Checkpoint.

Sun C, Mezzadra R, Schumacher TN.

Immunity. 2018 Mar 20;48(3):434-452. doi: 10.1016/j.immuni.2018.03.014. Review.

22.

Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.

Gee MH, Han A, Lofgren SM, Beausang JF, Mendoza JL, Birnbaum ME, Bethune MT, Fischer S, Yang X, Gomez-Eerland R, Bingham DB, Sibener LV, Fernandes RA, Velasco A, Baltimore D, Schumacher TN, Khatri P, Quake SR, Davis MM, Garcia KC.

Cell. 2018 Jan 25;172(3):549-563.e16. doi: 10.1016/j.cell.2017.11.043. Epub 2017 Dec 21.

23.

The Human Cell Atlas.

Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, Bodenmiller B, Campbell P, Carninci P, Clatworthy M, Clevers H, Deplancke B, Dunham I, Eberwine J, Eils R, Enard W, Farmer A, Fugger L, Göttgens B, Hacohen N, Haniffa M, Hemberg M, Kim S, Klenerman P, Kriegstein A, Lein E, Linnarsson S, Lundberg E, Lundeberg J, Majumder P, Marioni JC, Merad M, Mhlanga M, Nawijn M, Netea M, Nolan G, Pe'er D, Phillipakis A, Ponting CP, Quake S, Reik W, Rozenblatt-Rosen O, Sanes J, Satija R, Schumacher TN, Shalek A, Shapiro E, Sharma P, Shin JW, Stegle O, Stratton M, Stubbington MJT, Theis FJ, Uhlen M, van Oudenaarden A, Wagner A, Watt F, Weissman J, Wold B, Xavier R, Yosef N; Human Cell Atlas Meeting Participants.

Elife. 2017 Dec 5;6. pii: e27041. doi: 10.7554/eLife.27041.

24.

Antigen receptor repertoire profiling from RNA-seq data.

Bolotin DA, Poslavsky S, Davydov AN, Frenkel FE, Fanchi L, Zolotareva OI, Hemmers S, Putintseva EV, Obraztsova AS, Shugay M, Ataullakhanov RI, Rudensky AY, Schumacher TN, Chudakov DM.

Nat Biotechnol. 2017 Oct 11;35(10):908-911. doi: 10.1038/nbt.3979. No abstract available.

25.

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Mezzadra R, Sun C, Jae LT, Gomez-Eerland R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland I, Broeks A, Horlings HM, Wessels LFA, Blank CU, Xiao Y, Heck AJR, Borst J, Brummelkamp TR, Schumacher TNM.

Nature. 2017 Sep 7;549(7670):106-110. doi: 10.1038/nature23669. Epub 2017 Aug 16.

26.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

27.

HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.

Samuels S, Marijne Heeren A, Zijlmans HJMAA, Welters MJP, van den Berg JH, Philips D, Kvistborg P, Ehsan I, Scholl SME, Nuijen B, Schumacher TNM, van Beurden M, Jordanova ES, Haanen JBAG, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2017 Sep;66(9):1163-1173. doi: 10.1007/s00262-017-2006-y. Epub 2017 Apr 27.

PMID:
28451790
28.

Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.

Textor A, Schmidt K, Kloetzel PM, Weißbrich B, Perez C, Charo J, Anders K, Sidney J, Sette A, Schumacher TN, Keller C, Busch DH, Seifert U, Blankenstein T.

J Exp Med. 2017 Feb;214(2):567. doi: 10.1084/jem.2016063601122017c. Epub 2017 Jan 17. No abstract available.

29.

T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors.

Manzo T, Sturmheit T, Basso V, Petrozziello E, Hess Michelini R, Riba M, Freschi M, Elia AR, Grioni M, Curnis F, Protti MP, Schumacher TN, Debets R, Swartz MA, Corti A, Bellone M, Mondino A.

Cancer Res. 2017 Feb 1;77(3):658-671. doi: 10.1158/0008-5472.CAN-16-0725. Epub 2016 Nov 21.

30.

Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.

Textor A, Schmidt K, Kloetzel PM, Weißbrich B, Perez C, Charo J, Anders K, Sidney J, Sette A, Schumacher TN, Keller C, Busch DH, Seifert U, Blankenstein T.

J Exp Med. 2016 Oct 17;213(11):2333-2348. Epub 2016 Oct 3. Erratum in: J Exp Med. 2017 Feb;214(2):567.

31.

pMHC Multiplexing Strategy to Detect High Numbers of T Cell Responses in Parallel.

Philips D, van den Braber M, Schumacher TN, Kvistborg P.

Methods Mol Biol. 2017;1514:93-101.

PMID:
27787794
32.

Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ, Behjati S, Velds A, Hilkmann H, El Atmioui D, Visser M, Stratton MR, Haanen JB, Spits H, van der Burg SH, Schumacher TN.

Nat Med. 2016 Oct 6;22(10):1192. doi: 10.1038/nm1016-1192d. No abstract available.

PMID:
27711057
33.

Neoantigens encoded in the cancer genome.

Schumacher TN, Hacohen N.

Curr Opin Immunol. 2016 Aug;41:98-103. doi: 10.1016/j.coi.2016.07.005. Epub 2016 Aug 9. Review.

PMID:
27518850
34.

Editorial overview: Cancer immunology: genomics & biomarkers: Cancer immunity through the prism of genomics and proteomics.

Schumacher TN, Hacohen N.

Curr Opin Immunol. 2016 Aug;41:ix-x. doi: 10.1016/j.coi.2016.07.006. Epub 2016 Aug 6. No abstract available.

PMID:
27506117
35.

Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.

Dijkstra KK, Voabil P, Schumacher TN, Voest EE.

JAMA Oncol. 2016 Nov 1;2(11):1490-1495. doi: 10.1001/jamaoncol.2016.2214. Review.

PMID:
27491050
36.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher TN, Lo RS, Ribas A.

N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.

37.

Neoantigen landscape dynamics during human melanoma-T cell interactions.

Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup SR, van der Minne CE, Schotte R, Spits H, Haanen JB, Kapiteijn EH, Schumacher TN, van der Burg SH.

Nature. 2016 Aug 4;536(7614):91-5. Epub 2016 Jun 27.

PMID:
27350335
38.

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJC, Sun C, Voest EE, Ju YS, Schumacher TNM, Altelaar AFM, McDermott U, Adams DJ, Blank CU, Haanen JB, Peeper DS.

Cell Rep. 2016 Jun 28;16(1):263-277. doi: 10.1016/j.celrep.2016.05.064. Epub 2016 Jun 16.

39.

Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.

Strønen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Böschen ML, Lund-Johansen F, Olweus J, Schumacher TN.

Science. 2016 Jun 10;352(6291):1337-41. doi: 10.1126/science.aaf2288. Epub 2016 May 19.

40.

CANCER IMMUNOLOGY. The "cancer immunogram".

Blank CU, Haanen JB, Ribas A, Schumacher TN.

Science. 2016 May 6;352(6286):658-60. doi: 10.1126/science.aaf2834. No abstract available.

41.

A liquid biopsy for cancer immunotherapy.

Schumacher TN, Scheper W.

Nat Med. 2016 Apr;22(4):340-1. doi: 10.1038/nm.4074. No abstract available.

PMID:
27050586
42.

Reproducibility of Illumina platform deep sequencing errors allows accurate determination of DNA barcodes in cells.

Beltman JB, Urbanus J, Velds A, van Rooij N, Rohr JC, Naik SH, Schumacher TN.

BMC Bioinformatics. 2016 Apr 2;17:151. doi: 10.1186/s12859-016-0999-4.

43.

A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products.

Mezzadra R, Hollenstein A, Gomez-Eerland R, Schumacher TN.

Mol Ther Nucleic Acids. 2016 Mar 22;5:e298. doi: 10.1038/mtna.2016.13.

44.

The Branching Point in Erythro-Myeloid Differentiation.

Perié L, Duffy KR, Kok L, de Boer RJ, Schumacher TN.

Cell. 2015 Dec 17;163(7):1655-62. doi: 10.1016/j.cell.2015.11.059.

45.

T Cell Fate at the Single-Cell Level.

Buchholz VR, Schumacher TN, Busch DH.

Annu Rev Immunol. 2016 May 20;34:65-92. doi: 10.1146/annurev-immunol-032414-112014. Epub 2015 Dec 11. Review.

PMID:
26666651
46.

Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients.

Alanio C, Nicoli F, Sultanik P, Flecken T, Perot B, Duffy D, Bianchi E, Lim A, Clave E, van Buuren MM, Schnuriger A, Johnsson K, Boussier J, Garbarg-Chenon A, Bousquet L, Mottez E, Schumacher TN, Toubert A, Appay V, Heshmati F, Thimme R, Pol S, Mallet V, Albert ML.

Elife. 2015 Nov 14;4. pii: e07916. doi: 10.7554/eLife.07916.

47.

Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization.

Ariotti S, Beltman JB, Borsje R, Hoekstra ME, Halford WP, Haanen JB, de Boer RJ, Schumacher TN.

J Immunol. 2015 Dec 1;195(11):5285-95. doi: 10.4049/jimmunol.1500853. Epub 2015 Nov 2.

48.

Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Berkers CR, de Jong A, Schuurman KG, Linnemann C, Meiring HD, Janssen L, Neefjes JJ, Schumacher TN, Rodenko B, Ovaa H.

J Immunol. 2015 Nov 1;195(9):4085-95. doi: 10.4049/jimmunol.1402455. Epub 2015 Sep 23.

49.

Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage.

Berkers CR, de Jong A, Schuurman KG, Linnemann C, Geenevasen JA, Schumacher TN, Rodenko B, Ovaa H.

J Immunol. 2015 Nov 1;195(9):4075-84. doi: 10.4049/jimmunol.1402454. Epub 2015 Sep 23.

50.

Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy.

Kelderman S, Schumacher TN, Kvistborg P.

Cancer Cell. 2015 Jul 13;28(1):11-3. doi: 10.1016/j.ccell.2015.06.012.

Supplemental Content

Loading ...
Support Center